What makes an expert?

British Medical Journal

Volumn 334, Issue 7595, 2007, Pages 666-667

  Deer, Brian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; MERCURY DERIVATIVE; RISPERIDONE; THIOMERSAL; VACCINE; PRESERVATIVE;

AUTISM; BEHAVIOR DISORDER; CLINICAL EXAMINATION; COURT; HUMAN; LABORATORY TEST; MEDICAL SPECIALIST; PRECOCIOUS PUBERTY; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; SHORT SURVEY; UNITED STATES; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; EXPERT WITNESS; PUBLISHING; REVIEW;

AUTISTIC DISORDER; EXPERT TESTIMONY; HUMANS; PERIODICALS; PRESERVATIVES, PHARMACEUTICAL; RETRACTION OF PUBLICATION;

EID: 34247193677     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39146.498785.be     Document Type: Short Survey

References (7)

1. Geier DA, Geier MR. The biochemical basis and treatment of autism: interactions between mercury, transsulfurations, and androgens retracted. Autoimmunity Rev 2006 doi:10.1016/j.autrev.2006.09.014.
2. Siedel K. Significant misrepresentations: Mark Geier, David Geier and the evolution of the Lupron protocol (part thirteen): a silent withdrawal. Jan 23, 2007. http://neurodiversity.com/weblog/article/124/.
3. Neurodiversity page. ventura33.com/neurodiversity/.
4. Geier MR. Evolving views on the causes of autistic spectrum disorders. Lancet Neurol 2007;6:212.
5. Siedel K. Significant misrepresentations: Mark Geier, David Geier and the evolution of the Lupron protocol (portone): inaccurate byline. Jun 9, 2006. http://neurodiversity.com/weblog/article/97/.
6. Geier DA, Geier MR. A two phased population epidemiological study of the safety of thimeserol-containing vaccines: a follow-up analysis. Med Sci Mon 2005;11:CR160-70.
7. Siedel K. Significant misrepresentations: Mark Geier, David Geier and the evolution of the Lupron protocol (part eight): bibliographic mergers and acquisitions. Aug 10, 2006. http://neurodiversity.com/weblog/ article/108/bibliographic-mergers-acquisitions.